30
Dec
2020
Although the year was dominated by the response to covid-19, there were other major developments as well Read more
22
Dec
2020
As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more
17
Dec
2020
Failures to update IP management following the New Year could be costly for life sciences businesses Read more
16
Dec
2020
It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more
